Supplementary Table 2 from TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
收藏NIAID Data Ecosystem2026-04-25 收录
下载链接：
https://figshare.com/articles/dataset/Supplementary_Table_2_from_TBCRC023_A_Randomized_Phase_II_Neoadjuvant_Trial_of_Lapatinib_Plus_Trastuzumab_Without_Chemotherapy_for_12_versus_24_Weeks_in_Patients_with_HER2-Positive_Breast_Cancer/22472811
下载链接
链接失效反馈官方服务：
资源简介：
Characteristics of TBCRC023 Patients with disease progression
创建时间：
2020-02-15
